Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05335993 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer.

StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary completion date: Mar 30, 2025 to Dec 30, 2026 Completion date: Jul 30, 2025 to Dec 30, 2027 · Collaborators: 1 to 2v10 Show 2 more changesShow less
    • Completion date: Jul 30, 2025 to Dec 30, 2027
    • Collaborators: 1 to 2

    See this version in full on ClinicalTrials.gov ↗

  2. Primary completion date changed from estimate of Mar 30, 2024 to Mar 30, 2025 Completion date: Dec 30, 2024 to Jul 30, 2025v9 Show 1 more changeShow less
    • Completion date: Dec 30, 2024 to Jul 30, 2025
  3. Primary completion date: Jan 30, 2024 to Mar 30, 2024 Completion date: Oct 30, 2024 to Dec 30, 2024v8 Show 1 more changeShow less
    • Completion date: Oct 30, 2024 to Dec 30, 2024
  4. Primary completion date: Sep 30, 2023 to Jan 30, 2024 Completion date: May 30, 2024 to Oct 30, 2024v7 Show 1 more changeShow less
    • Completion date: May 30, 2024 to Oct 30, 2024
  5. Trial status: Recruiting to Active, Not Recruiting Primary completion date: May 30, 2023 to Sep 30, 2023 · Completion date: May 30, 2023 to May 30, 2024 · Site details revised at 3 of 3 sitesv6 Show 3 more changesShow less
    • Primary completion date: May 30, 2023 to Sep 30, 2023
    • Completion date: May 30, 2023 to May 30, 2024
    • Site details revised at 3 of 3 sites
Show 4 earlier versionsHide 4 earlier versions
  1. Start date changed from estimate of Jul 5, 2022 to Jul 25, 2022v5
  2. Start date: Apr 14, 2022 to Jul 5, 2022v4
  3. Site details revised at 1 of 3 sitesv3
  4. Trial status: Not Yet Recruiting to Recruiting Primary and study completion dates: Apr 30, 2023 to May 30, 2023 · Start date changed from estimate of Apr 30, 2022 to Apr 14, 2022 · Site details revised at 3 of 3 sitesv2 Show 3 more changesShow less
    • Primary and study completion dates: Apr 30, 2023 to May 30, 2023
    • Start date changed from estimate of Apr 30, 2022 to Apr 14, 2022
    • Site details revised at 3 of 3 sites
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Study to evaluate the safety and activity of oregovomab and niraparib as a combinatorial immune priming strategy in subjects with platinum sensitive recurrent ovarian cancer.
Trial Details
NCT Number NCT05335993
Lead Sponsor CanariaBio Inc.
Collaborators: Veristat, LLC, Raptim Research
Conditions Recurrent Ovarian Cancer, Recurrent Epithelial Cancer of Ovary, Recurrent Epithelial Ovarian Cancer, Recurrent Fallopian Tube Cancer, Peritoneal Cancer, Recurrent Carcinoma of Ovary, Adenocarcinoma of Ovary
Enrollment 10 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov